但这数字有可能改变:11月8号,全球健康革新科技基金宣布它的首笔用于改进疟疾、肺结核和锥虫病的治疗手手段的拨款。
The fund, launched earlier this year, is a public-private partnership that includes fiveJapanese drugmakers: Astellas, Daiichi Sankyo, Eisai, Shionogi and Takeda.
这基金成立于今年早些时候,是由5家公私合营的日本制药企业组成的,成员为Astellas, Daiichi Sankyo,Eisai, Shionogi and Takeda。
Criticism of pharma companies for restricting low-income countries access to drugs reached ahead at the turn of the millennium, when makers of life-saving HIV treatments refused toprovide them at affordable prices to patients in Africa.
在千年之交制药厂限制低收入国家购买药物途径,那时HIV治疗品制药厂拒绝以合理的价格将药品卖给非洲病人。
The resulting outrage forced the drug firms to rethink their policies.
这一行为遭到指责。而这一引起公愤的结果迫使制药公司重新思考他们的政策。
Today most of the biggest ones tout themselves as allies in the fight against infectiousdisease.
现在大多数大型制药公司作为联盟联合起来与传染疾病作斗争。
In some cases this means donating medicines, or licensing technology to makers of genericdrugs.
【2015考研英语阅读药物】相关文章:
最新
2016-10-18
2016-10-11
2016-10-11
2016-10-08
2016-09-30
2016-09-30